English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We would like to thank Dr. Van Hoef for her interesting remarks in this issue of the Journal[1][1] and acknowledge the fact that rituximab has produced some interesting data in the treatment of both acute and chronic graft- versus -host disease (GVHD). However, most studies cited by Dr. van Hoef

Reply to: Towards a rational graft-versus-host disease prophylaxis: rituximab should not be forgotten